Expression of Cyclin E and Its Relationship with the Prognosis of Patients with Breast Cancer

Objective： To investigate the expression of cyclin E in breast cancer tissues and its relationship with prognosis of the patients with breast cancer. Methods： The expression of cyclin E, HER-2/neu, nm23-H1 and actin was detected in 80 breast cancer tissues and 18 benign breast tumor tissues by immunohistochemical methods. The relationship between cyclin E and the remaining genes or the clinical data of the patients with breast cancer was analyzed. Results： The over expression rate of cyclin E in malignant tissues was obviously higher than that in benign tumor tissues （P〈0.01）. The over expression of cyclin E in later stage of disease was higher than that in early stage of disease （P〈0.05）. The expression of cyclin E in ER positive tissues was lower than that in ER negative tissues （P〈0.05）. The expression of cyclin E in PR positive tissues and PR negative tissues had no significant difference （P〉0.05）. The expression of cyclin E in HER-2/neu positive tissues was higher than that in HER-2/neu negative tissues （P〈0.05）. And the expression of cyclin E in ER, PR and HER-2/neu all positive tissues was much higher （P〈0.01）. There was no significant difference in the expression of cyclin E between nm23-H1 positive tissues and nm23-H1 negative tissues （P〉0.05）. The expression of cyclin E in actin positive and continuous distribution tissues was lower than that in actin negative or discontinuous distribution tissues （P〈0.05）. Conclusion： The expression of cyclin E has a strong correlation to the prognosis of the patients with breast cancer.     

The significance of minimally invasive core needle biopsy and immunohistochemistry analysis in 235 cases with breast lesions

OBJECTIVE To evaluate core needle biopsy （CNB） as a minimally invasive method to examine breast lesions and discuss the clinical significance of subsequent immunohistochemistry （IHC） analysis. METHODS The clinical data and pathological results of 235 patients with breast lesions, who received CNB before surgery, were analyzed and compared. Based on the results of CNB done before surgery; 87 out of 204 patients diagnosed as invasive carcinoma were subjected to immunodetection for p53, c-erbB-2, ER and PR. The morphological change of cancer tissues in response to chemo- therapy was also evaluated. RESULTS In total of 235 cases receiving CNB examination, 204 were diagnosed as invasive carcinoma, reaching a 100% consistent rate with the surgical diagnosis. Sixty percent of the cases diagnosed as non-invasive carcinoma by CNB was identified to have the presence of invading elements in surgical specimens, and similarly, 50% of the cases diagnosed as atypical ductal hyperplasia by CNB was confirmed to be carcinoma by the subsequent result of excision biopsy. There was no significant difference between the CNB biopsy and regular surgical samples in positive rate of immunohistochemistry analysis （p53, c-erbB-2, ER and PR; P 〉 0.05）. However, there was significant difference in the expression rate of p53 and c-erbB-2 between the cases with and without morphological change in response to chemotherapy （P 〈 0.05）. In most cases with p53 and c-erbB-2 positive, there was no obvious morphological change after chemotherapy. CONCLUSION CNB is a cost-effective diagnostic method with minimal invasion for breast lesions, although it still has some limitations. Immunodetection on CNB tissue is expected to have great significance in clinical applications.     

Significance of β-tubulin Expression in Breast Premalignant Lesions and Carcinomas

OBJECTIVE To explore the expression of β-tubulin in premalignant lesions and carcinomas of the breast, and to observe the relationship of its expression with breast cancer pathological features.METHODS The expression of β-tubulin was detected immunohistochemically in 50 specimens of premalignant lesions of the breast (ADH and Peri-PM with ADH), 50 specimens of breast in situ ductal carcinomas (DCIS), and 50 specimens of invasive ductal carcinomas (IDC). Thirty specimens of normal breast tissues served as a control group.RESULTS Immunohistochemical analysis showed that: the differences among the 4 groups (normal breast tissues, breast premalignant lesions, DCIS and IDC, P ＜ 0.05) were significant,and there were also statistically significant differences between any 2 groups (P ＜ 0.05) except for the β-tubulin positive expression comparing DCIS versus IDC (P ＞ 0.05). In addition, β-tubulin was expressed at a higher level in Peri-PM with ADH compared to ADH (P ＜ 0.05). Following the degree of breast epithelial hyperplasia involved, and its development into carcinoma, the β-tubulin positive expression displayed an elevating tendency.We also found a significant positive relationship of β-tubulin expression with lymph node metastasis (P ＜ 0.05), but no significant correlation with histological grading and nuclear grade.CONCLUSION Centrosome defects may be an early event in the development of breast cancer and they can also promote tumor progression. Studies of aberrations of centrosomal proteins provide a new way to explore the mechanism of breast tumorigenesis.     

SPECIFICITY AND SIGNIFICANCE OF LECTIN RECEPTORS IN BREAST CARCINOMA

Eight lectins were used to study 100 cases of breast carcinoma and 56 cases of non-carcinoma breast tissues by lectin affinity histochemical method. The results showed that Bandeirasa Simplicifolia (BSL) and Peanut agglutinin (PNA) had higher positive rates in breast carcinoma than both normal breast and benign lesions (P<0.005). The positive deposit in malignant lesions was mainly located in cytoplasm, while in non-malignant lesions, it was almost lined along the lumen of glands and small ducts (P<0.005). The authors think that expression of PNA-receptor in the cytoplasm might be associated with the mechanism that the tumor could escape from immune attack. Comparison analysis on the normal breast indicated that PNA affinity histoche-mistry would be useful to the understanding of the metabolism of β-D-galactosyl-N-acetyl-D-galactosa-mine during the development of normal breast and histological origin of breast carcinoma.     

Significance of β-tubulin Expression in Breast Premalignant Lesions and Carcinomas

OBJECTIVE To explore the expression of β-tubulin in premalignant lesions and carcinomas of the breast,and to observe the relationship of its expression with breast cancer pathological features. METHODS The expression of β-tubulin was detected immunohistochemically in 50 specimens of premalignant lesions of the breast(ADH and Peri-PM with ADH),50 specimens of breast in situ ductal carcinomas(DCIS),and 50 specimens of invasive ductal carcinomas(IDC).Thirty specimens of normal breast tissues served as a control group. RESULTS Immunohistochemical analysis showed that:the differences among the 4 groups(normal breast tissues,breast premalignant lesions,DCIS and IDC,P<0.05)were significant, and there were also statistically significant differences between any 2 groups(P<0.05)except for the β-tubulin positive expression comparing DCIS versus IDC(P>0.05).In addition,β-tubulin was expressed at a higher level in Peri-PM with ADH compared to ADH(P<0.05).Following the degree of breast epithelial hyperplasia involved,and its development into carcinoma,the β-tubulin positive expression displayed an elevating tendency. We also found a significant positive relationship of β-tubulin expression with lymph node metastasis(P<0.05),but no significant correlation with histological grading and nuclear grade. CONCLUSION Centrosome defects may be an early event in the development of breast cancer and they can also promote tumor progression.Studies of aberrations of centrosomal proteins provide a new way to explore the mechanism of breast tumorigenesis.     

EXPRESSION OF FRAGILE HISTIDINE TRIAD AND P53 IN NON-SMALL CELL LUNG CANCER

Objective： To investigate the expression offragile histidine triad （FHIT） and p53 protein in non-small cell lung cancer （NSCLC） and explore the relationship between their expressions and the clinicopathological features. Methods： FHIT protein and p53 protein were detected by immunohistochemistry in 76 cases of NSCLCs and matched normal lung tissues. Results： Fifty-one cases （67.1%） showed negative expression of FHIT （apparent reduction or loss） and thirty-seven cases （48.7%） showed p53 positive expression （overexpression）. The difference was significant （P=0.04）. However, there was no significant difference in FHIT expression between the p53-positive group and the p53-negative group （64.9% versus 69.2%, P=0.686）. The negative rate of FHIT protein expression was higher in squamous cell carcinoma than in adenocarcinoma, in moderately and poorly differentiated carcinoma than in well-differentiated carcinoma, and in cases with smoking history than in cases without smoking history （P〈0.05）. There was no relationship between FHIT expression and clinical stage or lymph node metastasis. The negative FHIT expression was not an independent predictor of overall survival （P=0.338）. Conclusion： The frequency of negative expression of FHIT protein is higher than that of positive expression of p53 in NSCLCs. The negative expression of FHIT is independent of the expression of p53. The change of expression of FHIT may play a role in the smoking related lung tumorigenesis while it may have no relationship with the progress of NSCLC or prognosis of the patients.     

Over-expression of EGFR in Breast Cancer

Objective： To explore the relationship of overexpression of epidermal growth factor receptor （EGFR） in occurrence, development and treatment of breast cancer. Methods： Samples of 46 breast adenoma tissues and 86 breast cancer tissues were regularly dehydrate-fixed, embedded in paraffin, sliced in to 5μm thick, stained with SABC immunohistochemistry and coloured with DAB. Results： The positive staining of EGFR was shown as brown- yellow and distributed in cytoplasm. The positive rates in the tissues of breast adenosis and breast cancer were 17.04% （6/46） and 56.98% （49/86） respectively. The positive rates of EGFR in the tissue of invasive ductal carcinoma was 64.49% （41/59）, which was significantly higher than that in in situ carcinoma （P〈0.05）. The positive rate of lymph metastasis group was higher than that in non-lymph metastasis group （P〈0.05）. Conclusion： The overexpression of EGFR was related with occurrence, lymph metastasis and pathologic types of breast cancer. The examination of EGFR in the breast cancer can serve as a guidance for target chemotherapy.     

THE EXPRESSION OF APOPTOSIS RELATED GENES IN THE PROCESS OF CANCERATION OF ATYPICAL HYPERPLASIA OF MAMMARY DUCT

Objective： To investigate the expression of apoptosis related genes p53 and bcl-2 in atypical hyperplasia of mammary duct and the relationship between the gene expression and oncogenesis of breast. Methods： mRNA of apoptosis related gene p53 and bcl-2 were detected by in situ hybridization in 44 cases of atypical ductal hyperplasia. p53 protein expression was detected by immunohistochemistry. The data were compared with those of 6 cases of benign hyperplasia and 26 cases of breast carcinoma. Results： The expression of p53 mRNA was 66.7% in benign hyperplasia, 40% in atypical ductal hyperplasia （55.6% in mild, 41.7% in medium, 26.1% in severe） and 19.2% in carcinoma （of which 21.4% were intraductal carcinoma and 16.7% were invasive）. The expression of p53 protein was negative in benign hyperplasia, 24% in atypical hyperplasia （mild 11.1%, medium 25%, severe 34.8%）, 38.5% in carcinoma （intraductal carcinoma 35.7%, invasive ductal carcinoma 41.7%）. The expression of bcl-2 was negative in benign hyperplasia, 78.6% in intraductal carcinoma, 83.3% in invasive ductal carcinoma. Conclusion： Loss and mutation of p53 gene and excessive expression bcl-2 mRNA were detected in severe atypical ductal hyperplasia.     

乳腺癌中端粒酶及凋亡相关蛋白的表达

 目的 探讨乳腺癌组织中端粒酶反转录酶（hTERT）及凋亡相关蛋白p53、bcl-2的表达与乳腺癌可能的发生机制间的关系。方法 应用免疫组织化学SP法对48例乳腺癌及配对癌旁组织、42例乳腺良性病变组织中hTERT、p53、bcl-2蛋白的表达进行检测。结果 48例乳腺癌hTERT、p53、bcl-2的表达率分别为87.50 %、56.25 %、54.17 %，与癌旁组织及乳腺良性疾病组相比，阳性表达率差异有统计学意义（P＜0.05）；hTERT阳性组p53、bcl-2的表达率分别为64.28 %、61.90 %，与阴性组相比差异有统计学意义（P＜0.05）。结论 端粒酶激活在乳腺癌发生过程中起重要作用，而p53基因突变及凋亡抑制基因bcl-2表达的下调在乳腺癌发生中起协同作用     

p16、p53、BRAF、Bcl-2在卵巢浆液性肿瘤组织中的表达及临床意义

目的:探讨卵巢浆液性肿瘤组织中p16、p53、BRAF、Bcl-2的表达及临床意义。方法:收集宁夏医科大学总医院病理科2017年至2018年确诊的卵巢浆液性肿瘤136例,其中浆液性囊腺瘤52例,交界性囊腺瘤22例,低级别浆液性癌18例,高级别浆液性癌44例;另收集卵巢良性肿瘤和卵巢癌手术切除标本各30例。分别采用免疫组织化学SP法检测p16、p53、BRAF、Bcl-2的表达,实时定量PCR法检测p16、p53在卵巢良恶性肿瘤组织中的表达。结果:卵巢浆液性囊腺瘤、交界性囊腺瘤、低/高级别浆液性癌组织中p16的阳性率分别为3.8%、45.5%、88.9%、81.8%,p53为0、9.1%、55.6%、45.5%,BRAF为46.2%、45.5%、22.2%、31.8%,Bcl-2为46.2%、45.5%、38.9%、47.7%。不同类型浆液性肿瘤组织中p16、p53表达均有显著性差异（P＜0.001）,但BRAF、Bcl-2表达未见明显差异。与卵巢良性肿瘤相比,p16在交界性肿瘤、卵巢癌中的阳性表达明显升高,差异有显著统计学意义（P＜0.012 5）;p53在卵巢癌中的阳性表达明显高于良性肿瘤（P＜0.001）;p16和p53的表达呈正相关（P＜0.05）。p53、Bcl-2与卵巢癌淋巴结转移有相关性（P＜0.001）,p16、p53、Bcl-2与盆腔侵犯有关（P＜0.05）,p53、BRAF、Bcl-2与CA125表达有不同程度相关性（P＜0.05）。p16、p53联合检测对卵巢癌诊断的敏感性和特异性为90.0%、76.7%。结论:p16、p53、BRAF、Bcl-2参与卵巢癌的发生发展,p16和p53基因突变可能在卵巢浆液性肿瘤的恶性进展中发挥作用,联合检测p16、p53对卵巢癌诊断有指示意义。     

分化抑制因子1、p53在人类乳腺癌中的表达及其临床意义

 目的　研究分化抑制因子1（Id1）、肿瘤抑制基因p53在乳腺癌组织中的表达及其相互关系,并探讨其意义。方法　选取2009年1月至2009年6月手术切除的乳腺癌组织标本80例,手术前均未经化疗和放疗等治疗,采用免疫组织化学方法检测Id1、p53在乳腺癌组织中的表达。结果　Id1表达于细胞质,p53表达于细胞核。Id1、p53在80例乳腺癌中的阳性表达率分别为87.5 %（70／80）、90.0 %（72／80）。Id1、p53在乳腺癌中的表达与在乳腺癌癌旁组织、乳腺良性肿瘤、正常乳腺组织中的表达均有统计学意义（P＜0.05）。乳腺癌的Idl表达与是否有腋窝淋巴结转移、肿瘤分期明显相关,而与患者年龄、肿瘤大小、组织分化无关。乳腺癌的p53表达与是否有腋窝淋巴结转移明显相关,而与患者年龄、肿瘤大小、组织分化、肿瘤分期无关。结论　Id1在人类乳腺癌中表达上调,Idl阳性率在有淋巴结转移组高于无淋巴结转移组,Id1在乳腺癌转移过程中起一定作用,Id1检测有利于判定乳腺癌的预后, 同时亦提示降低Id1表达可作为治疗乳腺癌转移的策略之一。Id1与p53均可作为判断乳腺癌患者淋巴结转移和预后的有效指标。     

乳腺癌及其癌前病变中细胞凋亡与p53、bcl-2蛋白的表达

目的：通过观察乳腺癌及其癌前病变中细胞凋亡调控基因ｐ５３、ｂｃｌ－２的表达,探讨细胞凋亡与凋亡调控基因在乳腺组织恶性转化进程中的作用。方法：利用ＤＮＡ缺口末端标记技术和免疫组织化学染色,原位观察３１例乳腺癌,２０例乳腺不典型增生和２０例乳腺单纯性增生中细胞凋亡和ｐ５３、ｂｃｌ－２蛋白的表达,以８例正常乳腺组织作为对照。结果：乳腺不典型增生和单纯性增生中细胞凋亡指数显著高于乳腺癌及正常乳腺组织（ｐ〉     

OTUD3和PTEN在乳腺癌组织中的表达及与临床病理特征和预后的关系

目的:检测乳腺癌组织中OTUD3与PTEN表达,分析其与临床病理特征及预后的关系。方法:选取2014年1月至2014年12月于我院行手术治疗的79例乳腺癌患者癌组织及其对应癌旁正常组织标本。采用免疫组化染色法、Western blot 检测、RT-PCR法分别检测癌组织及癌旁正常组织中OTUD3与PTEN表达,并分析两者表达相关性;探究OTUD3、PTEN与乳腺癌临床病理特征及预后的关系。结果:乳腺癌组织中PTEN阳性主要定位于细胞核,OTUD3阳性主要定位于细胞质。乳腺癌组织中OTUD3和PTEN阳性率、蛋白表达量及mRNA水平显著低于癌旁正常组织（P均<0.05）。乳腺癌组织中OTUD3、PTEN表达呈正相关（r=0.580,P=0.000）。PTEN与肿瘤直径、组织学分级、TNM分期、淋巴结转移、分子分型及ER/PR/HER-2/p53状态显著相关（P＜0.05）;OTUD3与组织学分级、TNM分期、淋巴结转移及p53显著相关（P＜0.05）。OTUD3及PTEN阴性表达组患者生存率显著低于阳性表达组（Log-rank检验P＜0.05）,两者不同表达是影响乳腺癌预后生存的独立危险因素之一（P＜0.05）。结论:乳腺癌组织中OTUD3、PTEN低表达,两者表达呈正相关,与组织学分级、TNM分期、淋巴结转移及p53等临床病理特征及预后显著相关,有望成为临床预后预测的有效因子。     

p53及bcl-2蛋白在乳腺癌中的表达及与c-erbB-2表达的相关性

目的探讨p53及bcl-2蛋白在乳腺癌中的表达情况,并分析其与c-erbB-2表达的相关性。方法选取50例乳腺癌患者,搜集其临床资料并进行回顾性分析,所有患者均行手术治疗并采集其乳腺癌组织(观察组,n=50)及癌旁正常乳腺组织(对照组,n=50)。采用免疫组化法检测并比较各组织标本中p53及bcl-2蛋白表达情况,分析其与乳腺癌组织病理分级的关系。另据乳腺癌组织中c-erbB-2蛋白表达情况分为c-erbB-2阳性组(n=37)及c-erbB-2阴性组(n=13),Person相关性分析评估p53、bcl-2蛋白与c-erbB-2蛋白表达的相关性。结果对照组及观察组中p53蛋白阳性表达率分别为0.00%、64.00%;bcl-2蛋白阳性表达率分别为88.00%、64.00%。观察组p53蛋白阳性表达率显著高于对照组,而观察组bcl-2蛋白阳性表达率显著低于对照组(P<0.01);p53蛋白阳性率随乳腺癌组织病理分级升高而逐渐升高,bcl-2蛋白阳性表达率随乳腺癌组织病理分级升高而逐渐降低,各级别间差异显著(P<0.05)。c-erbB-2阳性组中p53蛋白阳性表达率显著高于c-erbB-2阴性组,bcl-2蛋白阳性表达率显著低于c-erbB-2阴性组,且乳腺癌组织中p53蛋白与c-erbB-2蛋白表达显著正相关(γ=0.894,P<0.01),而bcl-2蛋白与c-erbB-2蛋白表达显著负相关(γ=-0.803,P<0.01)。结论乳腺癌组织中p53蛋白高表达,bcl-2蛋白低表达,且乳腺癌组织中p53蛋白与c-erbB-2蛋白表达显著正相关,而bcl-2蛋白与c-erbB-2蛋白表达显著负相关。     

EZH2和p53蛋白在前列腺癌中的表达及其临床意义

 【摘要】　目的　探讨EZH2和p53蛋白在前列腺癌组织中的表达及其临床意义。方法　通过组织芯片技术,应用EnVision免疫组织化学法检测48例术前无放化疗史的前列腺癌标本和15例良性前列腺增生组织中EZH2、p53蛋白的表达情况,并分析EZH2和p53蛋白在前列腺癌组织中的表达与临床病理特征关系以及两者间的相关性。结果　前列腺癌组织中EZH2和p53蛋白的阳性表达率分别为87.50 %（42／48）和33.33 %（16／48）,明显高于良性前列腺增生组织13.33 %（2／15）和0（0／15）（χ2＝26.429、χ2＝5.058,均P＜O.05）;EZH2和p53蛋白在前列腺癌中的表达均与Gleason分级、TNM分期相关（P＜0.05）,与患者年龄、前列腺特异性抗原（PSA）水平无关（P＞0.05）。在Gleason分级中,Gleason＞6分组阳性表达率高于Gleason≤6分组;TNM分期中,T3～T4期阳性表达率高于T1～T2期。Spearman等级相关分析显示,前列腺癌组织中EZH2和p53蛋白的表达呈正相关性（r＝0.294,P＜0.05）。结论　EZH2和p53可能共同参与了前列腺癌的发生、发展过程,联合检测EZH2和p53蛋白有望成为预测前列腺癌恶性程度进展的参考指标。同时也可能为临床治疗前列腺癌提供新的理论依据。     

Rsf-1在胃癌和癌前病变组织中的表达及临床意义

目的:染色质重塑因子1(chromatin remodeling factor 1,Rsf-1)可作为肿瘤靶向治疗的靶点,因此探讨其在胃癌(gastric cancer)及癌前病变(precancerous lesions)组织中的表达及临床意义。方法:采用免疫组化SP法检测30例萎缩性胃炎、30例肠上皮化生、22例不典型增生Rsf-1蛋白表达水平。并检测64例胃癌与配对癌旁组织(手术切缘距离肿瘤>5 cm)中Rsf-1和p53蛋白表达水平并分别分析与胃癌临床病理参数间的关系,同时分析Rsf-1与p53在胃癌中表达的相关性。结果:Rsf-1在胃癌、肠上皮化生、不典型增生组织中的阳性表达率均高于癌旁组织(P＜0.05)。Rsf-1在胃癌中表达与淋巴结转移有关(P＜0.05）。p53在胃癌中的阳性表达率高于癌旁组织,其表达与淋巴结转移有关(P＜0.05)。p53和Rsf-1在胃癌中的表达存在正相关性(r=0.38,P＜0.05),两者在胃癌中共阳性表达与淋巴结转移有关（P＜0.05)。结论:Rsf-1可能参与了胃癌病变的发生及发展,对胃癌早期筛查具有重要指导意义。Rsf-1和p53两者共阳性表达对于预测胃癌淋巴结转移可能具有一定的参考价值。     

乳腺癌组织中上皮钙黏蛋白和B细胞淋巴瘤基因2的表达及其临床意义的研究

目的:探讨乳腺癌中上皮钙黏蛋白（E-cadherin）和B细胞淋巴瘤基因2（Bcl-2）的表达及其临床意义。方法:使用免疫组织化学方法检测68例乳腺癌旁正常组织、41例纤维腺瘤组织和74例乳腺癌组织的E-cadherin和Bcl-2的表达水平,并分析乳腺癌患者各病理特征与E-cadherin和Bcl-2表达的相关性。结果:乳腺癌旁正常组织和纤维腺瘤组织中E-cadherin阳性率高于乳腺癌组织,Bcl-2阳性率低于乳腺癌组织,差异具有统计学意义（P均＜0.05）。乳腺癌组织病理分级越高、TNM分期越严重、有淋巴结转移和复发的患者 E-cadherin阳性率低,Bcl-2阳性率高;ER阳性患者E-cadherin阳性率高,Bcl-2阳性率高。组织病理分级低-中分化患者E-cadherin阳性率高于高分化患者,Bcl-2阳性率低于高分化患者,差异具有统计学意义（P均＜0.05）;TNM分期Ⅰ+Ⅱ期患者E-cadherin阳性率高于Ⅲ期,Bcl-2阳性率低于Ⅲ期,差异具有统计学意义（P均＜0.05）;有淋巴结转移患者E-cadherin阳性率低于无转移者,Bcl-2阳性率高于无转移者,差异具有统计学意义（P均＜0.05）;雌激素受体（ER）阴性患者E-cadherin、Bcl-2阳性率低于ER阳性者,差异具有统计学意义（P均＜0.05）;复发患者E-cadherin阳性率低于无复发者,Bcl-2阳性率高于无复发者,差异具有统计学意义（P均＜0.05）;Bcl-2的表达与E-cadherin的表达存在负相关性（r=-0.638,P＜0.05）。结论:乳腺癌组织中E-cadherin表达降低,Bcl-2表达升高,二者与乳腺癌组织病理分级、TNM分期、淋巴结转移、ER和复发有关,E-cadherin和Bcl-2的表达存在相关性。     

不同乳腺组织中肿瘤相关巨噬细胞与CXCL12表达的相关性

目的 探讨CXCL12表达和肿瘤相关巨噬细胞（TAMs）浸润在乳腺癌转移灶、乳腺癌原发灶及乳腺癌癌前病变中的相关性及其临床意义。方法 应用免疫组织化学法检测127例乳腺癌、71例乳腺癌转移灶、100例乳腺非典型导管增生、40例乳腺腺病组织中CXCL12的表达和TAMs的浸润情况。结果 CXCL12与TAMs在各组表达的阳性率分别为：乳腺腺病组为12.5%和7.5%,乳腺非典型导管增生组为39%和18%,乳腺癌原发灶组为63.8%和57.5%,乳腺癌转移灶组为78.9%和80.3%,CXCL12与TAMs在各组间表达水平的差异有统计学意义（P<0.001）,乳腺癌CXCL12与TAMs的表达分别与患者淋巴结转移、远处转移及临床TNM分期有关（P<0.05）,乳腺癌原发灶、乳腺癌转移灶TAMs浸润与CXCL12表达分别呈正相关（P<0.001）。结论 CXCL12与TAMs可能在乳腺癌的发生发展中发挥重要的协同作用,两者联合检测可作为乳腺癌患者淋巴结转移和远处转移的预测指标。